These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

993 related articles for article (PubMed ID: 12601523)

  • 1. Therapeutic vaccination with tumor cells that engage CD137.
    Hellstrom KE; Hellstrom I
    J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion.
    Zhang H; Knutson KL; Hellstrom KE; Disis ML; Hellstrom I
    Mol Cancer Ther; 2006 Jan; 5(1):149-55. PubMed ID: 16432173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment.
    Yang Y; Yang S; Ye Z; Jaffar J; Zhou Y; Cutter E; Lieber A; Hellström I; Hellström KE
    Cancer Res; 2007 Mar; 67(5):2339-44. PubMed ID: 17332366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.
    Ito F; Li Q; Shreiner AB; Okuyama R; Jure-Kunkel MN; Teitz-Tennenbaum S; Chang AE
    Cancer Res; 2004 Nov; 64(22):8411-9. PubMed ID: 15548712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice.
    Cuadros C; Dominguez AL; Lollini PL; Croft M; Mittler RS; Borgström P; Lustgarten J
    Int J Cancer; 2005 Oct; 116(6):934-43. PubMed ID: 15856473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
    Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
    Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB.
    Ye Z; Hellström I; Hayden-Ledbetter M; Dahlin A; Ledbetter JA; Hellström KE
    Nat Med; 2002 Apr; 8(4):343-8. PubMed ID: 11927939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
    Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
    An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137.
    Yang S; Yang Y; Raycraft J; Zhang H; Kanan S; Guo Y; Ronai Z; Hellstrom I; Hellstrom KE
    Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4990-5. PubMed ID: 15051893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy with agonistic anti-CD137: two sides of a coin.
    Sun Y; Chen JH; Fu Y
    Cell Mol Immunol; 2004 Feb; 1(1):31-6. PubMed ID: 16212918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB.
    Sharma S; Dominguez AL; Lustgarten J
    Exp Gerontol; 2006 Jan; 41(1):78-84. PubMed ID: 16289924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.
    Wilcox RA; Flies DB; Zhu G; Johnson AJ; Tamada K; Chapoval AI; Strome SE; Pease LR; Chen L
    J Clin Invest; 2002 Mar; 109(5):651-9. PubMed ID: 11877473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD137 monoclonal antibody promotes the direct anti-tumor effect mediated by peripheral blood-derived human dendritic cells in vitro.
    Zhang L; Wang Q; Wang X; Ding P; Song J; Ma C; Sun W
    Cell Mol Immunol; 2004 Feb; 1(1):71-6. PubMed ID: 16212924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.
    Melero I; Johnston JV; Shufford WW; Mittler RS; Chen L
    Cell Immunol; 1998 Dec; 190(2):167-72. PubMed ID: 9878117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo.
    Yan X; Johnson BD; Orentas RJ
    Immunology; 2004 May; 112(1):105-16. PubMed ID: 15096190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens.
    Tirapu I; Arina A; Mazzolini G; Duarte M; Alfaro C; Feijoo E; Qian C; Chen L; Prieto J; Melero I
    Int J Cancer; 2004 May; 110(1):51-60. PubMed ID: 15054868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
    May KF; Chen L; Zheng P; Liu Y
    Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies.
    Murillo O; Arina A; Tirapu I; Alfaro C; Mazzolini G; Palencia B; López-Diaz De Cerio A; Prieto J; Bendandi M; Melero I
    Clin Cancer Res; 2003 Nov; 9(15):5454-64. PubMed ID: 14654524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.